Comparing early and delayed brain radiotherapy with Almonertinib for lung cancer patients with brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of early versus delayed brain radiotherapy combined with the EGFR-TKI Almonertinib in patients with non-small cell lung cancer (NSCLC) who have brain metastases. Participants are randomly assigned to receive brain radiotherapy either within one month of starting TKI treatment or within three months after brain progression. The study aims to compare overall survival, progression-free survival, safety, neurocognitive function, and quality of life between the two groups. This multicenter, randomized, controlled trial focuses on patients with specific EGFR mutations and limited brain metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically or cytologically confirmed non-small cell lung cancer;
* Initial diagnosis of intracranial oligometastases (no treatment after brain metastases) was defined as brain parenchymal metastases confirmed by MRI, the number of intracranial parenchymal metastases was less than 5, and the lesions were 3mm away from the optic nerve and brainstem; There must be at least one measurable lesion with a diameter of 5mm or more in the brain.
* EGFR sensitivity mutation (exon19del or exon21 L858R);
* Anti-EGFR-targeting drugs and other TKI drugs have not been used in the past;
* Age 18-75;

Inclusion criteria:

* A history (past or concurrent) of malignancies in other sites, excluding curable non-melanoma skin cancer and cervical carcinoma in situ;
* The subjects had received brain radiotherapy before enrollment;
* Patients whose lung lesions were surgically evaluated as resectable were not included if there was no metastasis in other parts of the body;
* Received EGFR inhibitors (including small molecule or monoclonal antibody therapy) or systematic anti-tumor therapy before treatment;
* Prior patients with interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy, or any clinically proven active interstitial lung disease with idiopathic pulmonary fibrosis found on CT scan at baseline;
* Pregnant and lactating patients;
* MRI contraindicated patients;
* Patients who cannot receive oral administration, need intravenous high-energy nutrition, have undergone previous surgery that interferes with absorption, or have active digestive tract ulcers;
* The researchers judged that brain radiotherapy could not be received because of other head and facial diseases;
* Any unstable systemic disease (including active infection, poorly controlled hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic disease).

Where it's running

• Sun-Yat-Sen university
  Guangdong, Guangzhou, China Recruiting

Study contacts

• Principal investigator: Likun Chen — sunyat-sen university cancer center
• Study coordinator: Likun Chen, Ph.D
• Email: chenlk@sysucc.org.cn
• Phone: +8613798019964

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trastuzumab rezetecan with or without radiotherapy for HER2‑positive advanced breast cancer that has spread to the brain.

  This trial will test whether adding radiotherapy to trastuzumab rezetecan helps adults with HER2‑positive advanced breast cancer and untreated brain metastases control their brain tumors better than the drug alone.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07100600

• Evaluating TY-9591 for treating advanced lung cancer with brain metastases

  This study is testing a new drug called TY-9591 to see if it can help people with advanced lung cancer that has spread to the brain, compared to a standard treatment.

  Recruiting Phase 2 TYK Medicines, Inc · Beijing, Beijing Municipality · NCT05948813

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.